Immune Design buries its PhIII work on cancer, and investors hit the panic button
More than a year after touting some early glimmers of success for a combination of their drug CMB305 and Tecentriq (atezolizumab), Immune Design is throwing in the towel after determining that their ongoing Phase II program is headed to failure.
Investors are not in the least pleased with the changeup for CMB305, their lead drug. The biotech’s shares $IMDZ shed half their value after the decision was announced.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.